Market Data
Market Cap₹1,402.7 Cr.
52W High₹293.65
Current Price₹290.5
52W Low₹107
Down from 52W High1.1 %
Face Value₹10
Performance
ROCE6.51 %
ROE4.71 %
EPS (TTM)₹1.39
EPS Prev Qtr₹3.91
EPS Last Year₹-2.06
EBITDA Qtr₹10.03 Cr.
Book Value₹110
Financial Health
Debt/Equity0.29
Debt/Profit6.11
Total Assets₹908.362 Cr.
Dividend Yield1.03 %
Promoter Holding44.42 %
Earning Power4.65 %
Valuation
Stock P/E56.19
Industry P/E33.3
Price to Book2.65
Price to Sales2
Graham Number₹112.92
Key Metrics
Face Value
₹10
About Kopran Ltd
Healthcare · Pharmaceuticals
Kopran Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹1,402.7 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a healthy promoter holding of 44.42%, indicating strong control and alignment of interests.
- The company has a manageable debt-to-equity ratio of 0.29, suggesting a conservative capital structure.
Weaknesses
- The P/E ratio of 45.58 is relatively high, indicating that the stock may be overvalued compared to its earnings.
- The P/B ratio of 2.15 suggests that the market values the company at a premium over its book value.
- The ROCE of 6.51% is relatively low, indicating that the company is not efficiently using its capital to generate profits.
- The ROE of 4.71% is low, suggesting that the company is not effectively generating returns on its equity.
- The dividend yield of 1.27% is low, which may not be attractive to income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 117.91 | 194.28 | 234.02 | 153.99 |
| ↳ QoQ Growth | - | +64.8% | +20.5% | -34.2% |
| Expenses | 127.47 | 180.93 | 205.59 | 143.96 |
| Operating Profit | -9.56 | 13.35 | 28.43 | 10.03 |
| OPM % | -8.11% | 6.87% | 12.15% | 6.51% |
| Other Income | 0.03 | 0.07 | 0.09 | 2.05 |
| Interest | 2.09 | 2.67 | 3.17 | 3.28 |
| Depreciation | 4.28 | 4.42 | 4.52 | 5.77 |
| EBITDA | -5.28 | 17.77 | 32.95 | 15.8 |
| EBITDA Margin % | -4.48% | 9.15% | 14.08% | 10.26% |
| Profit Before Tax | -11.63 | 10.74 | 25.35 | 8.8 |
| Tax % | 14.62% | 13.04% | 25.56% | 23.86% |
| Net Profit | -9.92 | 9.34 | 18.87 | 6.7 |
| ↳ QoQ Growth | - | +194.2% | +102.0% | -64.5% |
| EPS | -2.06 | 1.93 | 3.91 | 1.39 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 48.29 | 48.2856 |
| Reserves | 470.06 | 481.9949 |
| Borrowings | 147.78 | 152.69 |
| Other Liabilities | 177.88 | 225.39 |
| Total Liabilities | 844.01 | 908.3624 |
| Fixed Assets | 196.65 | 368.9101 |
| CWIP | 99.38 | 2.3266 |
| Investments | 0.06 | 0.06 |
| Other Assets | 547.92 | 537.07 |
| Total Assets | 844.01 | 908.3624 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 41.9421 |
| Cash from Investing Activity | -56.428 |
| Cash from Financing Activity | 25.8675 |
| Net Cash Flow | 11.3816 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 44.42% | 44.42% | 44.42% | 44.42% |
| FIIs % | 0.6% | 0.36% | 0.57% | 0.51% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 44.65% | 44.71% | 44.08% | 44.14% |
| No. of Shareholders | 62,222 | 60,886 | 58,639 | 56,925 |
Major Shareholders (>1%)
- Oricon Enterprises LimitedPromoter and Promoter Group12.88%
- Panorama Finvest Pvt LtdPromoter and Promoter Group7.87%
- Sarvamangal Mercantile Co LtdPromoter and Promoter Group6.01%
- United Shippers LtdPromoter and Promoter Group4.56%
As of 2026-06-30View all shareholders →